MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.

Aldea M, Lenahan SM, Locquet MA, Liao L, Gasparro M, Gokhale PC, Ghigna MR, Ionescu DN, Odintsov I, Ngo K, Wang X, Aziz S, Pecci F, Garbo E, Ivanova E, Nakazawa S, Kulesza J, Tsai JA, Zullo L, Lee J, Zielinska M, Simon S, Han D, Marinello A, Li G, Rossato de Almeida G, Huang J, Paoloni F, Gariazzo E, Santo V, Remon J, Marks JA, LoPiccolo J, Florez N, Nishino M, Ricciuti B, Luo J, Barbie DA, Planchard D, Rotow JK, Barlesi F, Graf RP, Feng WW, Besse B, Paweletz C, Sholl L, Shaw AT, Jänne PA

Open source

DOI
10.1016/j.annonc.2026.03.001
Published
2026 Jul
Container
Annals of oncology : official journal of the European Society for Medical Oncology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.annonc.2026.03.001,
  title = {MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.},
  author = {Aldea M and Lenahan SM and Locquet MA and Liao L and Gasparro M and Gokhale PC and Ghigna MR and Ionescu DN and Odintsov I and Ngo K and Wang X and Aziz S and Pecci F and Garbo E and Ivanova E and Nakazawa S and Kulesza J and Tsai JA and Zullo L and Lee J and Zielinska M and Simon S and Han D and Marinello A and Li G and Rossato de Almeida G and Huang J and Paoloni F and Gariazzo E and Santo V and Remon J and Marks JA and LoPiccolo J and Florez N and Nishino M and Ricciuti B and Luo J and Barbie DA and Planchard D and Rotow JK and Barlesi F and Graf RP and Feng WW and Besse B and Paweletz C and Sholl L and Shaw AT and Jänne PA},
  year = {2026},
  journal = {Annals of oncology : official journal of the European Society for Medical Oncology},
  doi = {10.1016/j.annonc.2026.03.001},
  url = {https://doi.org/10.1016/j.annonc.2026.03.001}
}

RIS

TY  - JOUR
TI  - MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.
AU  - Aldea M
AU  - Lenahan SM
AU  - Locquet MA
AU  - Liao L
AU  - Gasparro M
AU  - Gokhale PC
AU  - Ghigna MR
AU  - Ionescu DN
AU  - Odintsov I
AU  - Ngo K
AU  - Wang X
AU  - Aziz S
AU  - Pecci F
AU  - Garbo E
AU  - Ivanova E
AU  - Nakazawa S
AU  - Kulesza J
AU  - Tsai JA
AU  - Zullo L
AU  - Lee J
AU  - Zielinska M
AU  - Simon S
AU  - Han D
AU  - Marinello A
AU  - Li G
AU  - Rossato de Almeida G
AU  - Huang J
AU  - Paoloni F
AU  - Gariazzo E
AU  - Santo V
AU  - Remon J
AU  - Marks JA
AU  - LoPiccolo J
AU  - Florez N
AU  - Nishino M
AU  - Ricciuti B
AU  - Luo J
AU  - Barbie DA
AU  - Planchard D
AU  - Rotow JK
AU  - Barlesi F
AU  - Graf RP
AU  - Feng WW
AU  - Besse B
AU  - Paweletz C
AU  - Sholl L
AU  - Shaw AT
AU  - Jänne PA
PY  - 2026
JO  - Annals of oncology : official journal of the European Society for Medical Oncology
DO  - 10.1016/j.annonc.2026.03.001
UR  - https://doi.org/10.1016/j.annonc.2026.03.001
ER  -

APA

M, A., SM, L., MA, L., L, L., M, G., PC, G., MR, G., DN, I., I, O., K, N., X, W., S, A., F, P., E, G., E, I., S, N., J, K., JA, T., L, Z., J, L., M, Z., S, S., D, H., A, M., G, L., G, R. D. A., J, H., F, P., E, G., V, S., J, R., JA, M., J, L., N, F., M, N., B, R., J, L., DA, B., D, P., JK, R., F, B., RP, G., WW, F., B, B., C, P., L, S., AT, S., & PA, J. (2026). MTAP loss is frequent in oncogene-driven NSCLC and may confer sensitivity to combined PRMT5 inhibitors and targeted therapies.. Annals of oncology : official journal of the European Society for Medical Oncology. https://doi.org/10.1016/j.annonc.2026.03.001

Source records